Gundala Venkata Naveen Kumar

Gundala Venkata Naveen Kumar

Auto-generated profile, based on publicly available information

Gundala Venkata Naveen Kumar

Department of Pharmaceutical Sciences and Center for Pharmacogenetics, University of Pittsburgh School of Pharmacy, Pittsburgh, PA 15261, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2021 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
GKGundala Venkata Naveen Kumar
Gundala Venkata Naveen Kumar
KHKeito Hoshitsuki
Keito Hoshitsuki
Sanjay RathodSanjay Rathod
Sanjay Rathod
MRManda J. Ramsey
Manda J. Ramsey
LKLauren Kokai
Lauren Kokai
CFChristian A Fernandez
Christian A Fernandez
PEGylated-l-asparaginase (PEG-ASNase) is a chemotherapeutic agent used to treat pediatric acute lymphoblastic leukemia (ALL). Its use is avoided in adults due to its high risk of liver injury including hepatic steatosis, with obesity and older age considered risk factors of the injury. Our study aims to elucidate the mechanism of PEG-ASNase-induced liver injury. Mice received 1500 U/kg of PEG-ASNase and were sacrificed 1, 3, 5, and 7 days after drug administration. Liver triglycerides were quantified, and plasma bilirubin, ALT, AST, and non-esterified fatty acids (NEFA) were measured. The mRNA and protein levels of genes involved in hepatic fatty acid synthesis, β-oxidation, very low-density lipoprotein (VLDL) secretion, and white adipose tissue (WAT) lipolysis were determined. Mice developed hepatic steatosis after PEG-ASNase, which associated with increases in bilirubin, ALT, and AST. The hepatic genes Ppara, Lcad/Mcad, Hadhb, Apob100, and Mttp were upregulated, and Srebp-1c and Fas were downregulated after PEG-ASNase. Increased plasma NEFA, WAT loss, and adipose tissue lipolysis were also observed after PEG-ASNase. Furthermore, we found that PEG-ASNase-induced liver injury was exacerbated in obese and aged mice, consistent with clinical studies of ASNase-induced liver injury. Our data suggest that PEG-ASNase-induced liver injury is due to drug-induced lipolysis and lipid redistribution to the liver.

2 October 2026 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
WQWanning Qiao
Wanning Qiao
CKCun Ku
Cun Ku
GKG. V. Naveen Kumar
G. V. Naveen Kumar
JBJonathan D. Brown
Jonathan D. Brown
MWManni Wu
Manni Wu
YZYang Zhang
Yang Zhang
Background and Purpose: The nuclear receptor NR4A1 is a critical node in transcriptional circuits for metabolic adaptation, yet its role in adipocyte progenitor (AP) fate and proliferation is unclear. We sought to define how NR4A1 governs early adipogenesis and adipose tissue plasticity. Experimental Approach: Doxycycline‐inducible NR4A1‐overexpressing and NR4A1‐deficient 3T3‐L1 models were used to assess lipid accumulation, mitotic clonal expansion (MCE), and cell‐cycle dynamics. Multiomics integration (RNA‐seq and chromatin assays) identified NR4A1 targets. The functionality of two lead candidates, ANLN and CDC20, was tested by genetic knockdown and pharmacological inhibition. Diet‐induced obese mice received the NR4A1 antagonist C‐DIM8 alone or combined with the PPARγ agonist rosiglitazone to evaluate adipose expansion and metabolic outcomes. Key Results: NR4A1 exerted a stage‐specific inhibitory effect during early differentiation, reducing expression of canonical adipogenic markers and lipid accumulation. Integrative transcriptomic and chromatin analyses identified Anln and Cdc20 as direct NR4A1 targets essential for MCE. Depletion of either gene phenocopied NR4A1 overexpression, inducing G2/M arrest and blunting of adipogenesis. Pharmacological CDC20 inhibition with Apcin suppressed preadipocyte proliferation and differentiation in a dose‐dependent manner. Importantly, in a diet‐induced obese mouse model, combined treatment with the NR4A1 antagonist C‐DIM8 and the PPARγ agonist rosiglitazone promoted AP proliferation, hyperplastic adipose tissue expansion, and improved glucose tolerance. Conclusions and Implications: NR4A1 functions as a transcriptional gatekeeper of adipogenic initiation by restraining the Anln / Cdc20 cell‐cycle program. Pharmacological modulation of the NR4A1–cell‐cycle axis, particularly alongside PPARγ activation, may offer a strategy to augment adipose tissue plasticity and metabolic resilience in obesity.